Name: UMIN ID:
Unique ID issued by UMIN | UMIN000009297 |
---|---|
Receipt number | R000010909 |
Scientific Title | Randomized phase II study comparing trastuzumab plus weekly paclitaxel with weekly paclitaxel alone for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. |
Date of disclosure of the study information | 2012/11/09 |
Last modified on | 2023/01/10 09:39:38 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/11/09 13:21:46 | ||
2 | Update | 2013/01/30 10:00:24 | Recruitment status |
|
3 | Update | 2013/01/30 10:01:52 | Public title |
|
4 | Update | 2013/01/30 10:05:06 | Condition Narrative objectives1 Key secondary outcomes |
|
5 | Update | 2013/01/30 10:10:38 | Key inclusion criteria Key exclusion criteria |
|
6 | Update | 2016/07/28 09:47:44 | Organization Division name Division name Address Address TEL Name of primary person or sponsor Organization Organization Organization Category of Funding Organization |
|
7 | Update | 2017/01/10 10:01:15 | Recruitment status |
|
8 | Update | 2018/05/15 11:28:04 | Organization |
|
9 | Update | 2018/11/15 10:08:20 | Recruitment status Publication of results |
|
10 | Update | 2023/01/10 09:39:38 | Recruitment status Date of IRB Last follow-up date |